Methods Our retrospective cohort study utilized TriNetX Research Network to compare IIH patients treated with GLP-1 RAs to untreated controls
The hope is that results will be available for regulators to review by the end of 2025
Among these, glucagon-like peptide-1 (GLP-1) receptor agonists, which are already approved for weight management and type 2 diabetes, have shown promise
This reduced frequency means less overall needle exposure and fewer opportunities for discomfort
The medication is administered as a once-weekly subcutaneous injection, starting with a non-therapeutic initiation dose of 0.25 mg for 4 weeks, then titrating to maintenance doses of 0.5 mg, 1 mg, or 2 mg depending on individual response and tolerability
The abdomen provides the most accessible location for self-injection, with the area 2 or more inches from the navel offering appropriate subcutaneous tissue depth